Fungemia due to rare opportunistic yeasts: Data from a population-based surveillance in Spain

Medical Mycology

Volumn 55, Issue 2, 2017, Pages 125-136

  Fernández Ruiz, Mario ^a   Guinea, Jesus ^b   Puig Asensio, Mireia ^c   Zaragoza, Oscar ^d   Almirante, Benito ^c   Cuenca Estrella, Manuel ^d   Aguado, José María ^a  

^a Universidad Complutense   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Fungemia; Non Candida species; Opportunistic yeasts; Rhodotorula; Trichosporon

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; ANTIFUNGAL AGENT; FUNGAL DNA;

ANTIFUNGAL SUSCEPTIBILITY; ANTIFUNGAL THERAPY; ARTICLE; CANDIDEMIA; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CYBERLINDNERA; CYBERLINDNERA FABIANII; DNA SEQUENCE; FEMALE; FUNGEMIA; HEMATOLOGIC MALIGNANCY; HOSPITAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KODAMAEA OHMERI; LODDEROMYCES ELONGISPORUS; MAGNUSIOMYCES CAPITATUS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PICHIA KUDRIAVZEVII; POPULATION RESEARCH; RHODOTORULA MUCILAGINOSA; RISK FACTOR; SPAIN; SPECIES IDENTIFICATION; TRICHOSPORON ASAHII; WICKERHAMOMYCES ANOMALUS; ADULT; AGED; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; YEAST;

ADULT; AGED; ANTIFUNGAL AGENTS; DNA, FUNGAL; EPIDEMIOLOGICAL MONITORING; FEMALE; FUNGEMIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SPAIN; YEASTS;

EID: 85017079132     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myw055     Document Type: Article

References (50)

1. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-1703.
2. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117-123.
3. Arendrup MC, Dzajic E, Jensen RH et al. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013; 19: E343-353.
4. Arendrup MC, Boekhout T, Akova M et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2014; 20 (Suppl 3): 76-98.
5. Chitasombat MN, Kofteridis DP, Jiang Y et al. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect 2012; 64: 68-75.
6. De Almeida GM, Costa SF, Melhem M et al. Rhodotorula spp. isolated from blood cultures: clinical and microbiological aspects. Med Mycol 2008; 46: 547-556.
7. Lockhart SR, Messer SA, Pfaller MA et al. Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J Clin Microbiol 2008; 46: 374-376.
8. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142-151.
9. Suzuki K, Nakase K, Kyo T et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol 2010; 84: 441-447.
10. Taj-Aldeen SJ, Abdul Wahab A, Kolecka A et al. Uncommon opportunistic yeast bloodstream infections from Qatar. Med Mycol 2014; 52: 552-556.
11. Martino R, Salavert M, Parody R et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis 2004; 38: 335-341.
12. Fores R, Ramos A, Orden B et al. Rhodotorula species fungaemia causes low mortality in haematopoietic stem-cell transplantation. A case report and review. Mycoses 2012; 55: e158-162.
13. Gabriel F, Noel T, Accoceberry I. Lindnera (Pichia) fabianii blood infection after mesenteric ischemia. Med Mycol 2012; 50: 310-314.
14. Adami F, Scarin M, Pescarini L et al. Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B. Mycoses 2011; 54: 365-369.
15. Ersoz G, Otag F, Erturan Z et al. An outbreak of Dipodascus capitatus infection in the ICU: three case reports and review of the literature. Jpn J Infect Dis 2004; 57: 248-252.
16. Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev Iberoam Micol 2008; 25: 135-140.
17. Liao Y, Lu X, Yang S et al. Epidemiology and outcome of Trichosporon fungemia: a review of 185 reported cases from 1975 to 2014. Open Forum Infect Dis 2015; 2: doi: 10.1093/ofid/ofv141.
18. Gadea I, Cuenca-Estrella M, Prieto E et al. Genotyping and antifungal susceptibility profile of Dipodascus capitatus isolates causing disseminated infection in seven hematological patients of a tertiary hospital. J Clin Microbiol 2004; 42: 1832-1836.
19. Garcia-Ruiz JC, Lopez-Soria L, Olazabal I et al. Invasive infections caused by Saprochaete capitata in patients with haematological malignancies: report of five cases and review of the antifungal therapy. Rev Iberoam Micol 2013; 30: 248-255.
20. Puig-Asensio M, Padilla B, Garnacho-Montero J et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2014; 20: 245-254.
21. Guinea J, Zaragoza O, Escribano P et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother 2014; 58: 1529-1537.
22. Fernandez-Ruiz M, Aguado JM, Almirante B et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis 2014; 58: 1413-1421.
23. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
24. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
25. White TBT, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA GD, Sninsky JJ, White TJ, (Eds.) PCR Protocols: A Guide to Methods and Applications. San Diego, CA: Academic Press; 1990, 315-322.
26. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008; 14: 398-405.
27. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard (3rd edition). CLSI document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
28. Peman J, Canton E, Quindos G et al. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67: 1181-1187.
29. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49: 4026-4034.
30. Araujo Ribeiro M, Alastruey-Izquierdo A, Gomez-Lopez A et al. Molecular identification and susceptibility testing of Trichosporon isolates from a Brazilian hospital. Rev Iberoam Micol 2008; 25: 221-225.
31. Kurtzman CP Phylogeny of the ascomycetous yeasts and the renaming of Pichia anomala to Wickerhamomyces anomalus. Antonie Van Leeuwenhoek 2011; 99: 13-23.
32. Goss G, Grigg A, Rathbone P et al. Hansenula anomala infection after bone marrow transplantation. Bone Marrow Transplant 1994; 14: 995-997.
33. Chan AW, Cartwright EJ, Reddy SC et al. Pichia anomala (Candida pelliculosa) fungemia in a patient with sickle cell disease. Mycopathologia 2013; 176: 273-277.
34. Aragao PA, Oshiro IC, Manrique EI et al. Pichia anomala outbreak in a nursery: exogenous source? Pediatr Infect Dis J 2001; 20: 843-848.
35. Pasqualotto AC, Sukiennik TC, Severo LC et al. An outbreak of Pichia anomala fungemia in a Brazilian pediatric intensive care unit. Infect Control Hosp Epidemiol 2005; 26: 553-558.
36. da Silva CM, de Carvalho Parahym AM, Leao MP et al. Fungemia by Candida pelliculosa (Pichia anomala) in a neonatal intensive care unit: a possible clonal origin. Mycopathologia 2013; 175: 175-179.
37. Kalenic S, Jandrlic M, Vegar V et al. Hansenula anomala outbreak at a surgical intensive care unit: a search for risk factors. Eur J Epidemiol 2001; 17: 491-496.
38. Bhally HS, Jain S, Shields C et al. Infection in a neonate caused by Pichia fabianii: importance of molecular identification. Med Mycol 2006; 44: 185-187.
39. Grenouillet F, Millon L, Chamouine A et al. Pichia fabianii Fungemia in a Neonate. Pediatr Infect Dis J 2010; 29: 191.
40. Yun JW, Park KS, Ki CS et al. Catheter-related bloodstream infection by Lindnera fabianii in a neutropenic patient. J Med Microbiol 2013; 62: 922-925.
41. Mohl W, Lerch MM, Klotz M et al. Infection of an intravenous port system with Metschnikowia pulcherrima Pitt et Miller. Mycoses 1998; 41: 425-426.
42. Hamal P, Ostransky J, Dendis M et al. A case of endocarditis caused by the yeast Pichia fabianii with biofilm production and developed in vitro resistance to azoles in the course of antifungal treatment. Med Mycol 2008; 46: 601-605.
43. Wirth F, Goldani LZ. Epidemiology of Rhodotorula: an emerging pathogen. Interdiscip Perspect Infect Di 2012; 2012: 465717.
44. Lunardi LW, Aquino VR, Zimerman RA et al. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006; 43: e60-63.
45. Zaas AK, Boyce M, Schell W et al. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 2003; 41: 5233-5235.
46. Subramanya Supram H, Gokhale S, Chakrabarti A et al. Emergence of Magnusiomyces capitatus infections in Western Nepal. Med Mycol 2016; 54: 103-110.
47. Girmenia C, Pizzarelli G, D'Antonio D et al. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother 2003; 47: 3985-3988.
48. Guinea J, Recio S, Escribano P et al. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother 2010; 54: 4012-4015.
49. Chittick P, Palavecino EL, Delashmitt B et al. Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy. Antimicrob Agents Chemother 2009; 53: 5306-5307.
50. Schuermans C, van Bergen M, Coorevits L et al. Breakthrough Saprochaete capitata infections in patients receiving echinocandins: case report and review of the literature. Med Mycol 2011; 49: 414-418.